|
|
|
|
A high-performing cell line, optimized reagents, and purpose-built technology are tested and proven in a perfusion process with data that supports scalability, productivity and higher quality drug products for gene therapy applications.
|
|
|
|
|
While the promise of AAV gene therapy is immense, traditional manufacturing has relied on “brute force” methods that are costly and inefficient. VintaBio is driving the evolution of AAV by harnessing a “scaling through nature” philosophy. Our purpose-built process creates a low-stress environment that mimics the natural, adherent state of the cells - allowing them to be more production.
|
|
|
|
|
Review how intensified adherent cell culture is challenging the dominance of suspension systems in viral vector production, offering improved productivity, reduced impurities, and scalable solutions that better align with the natural behavior of HEK 293 cells.
|
|
|
|
|
|
|
